Values First Advisors Inc. Purchases 476 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Values First Advisors Inc. lifted its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 7.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,983 shares of the biopharmaceutical company’s stock after acquiring an additional 476 shares during the quarter. Values First Advisors Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,337,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Altfest L J & Co. Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 29.7% in the fourth quarter. Altfest L J & Co. Inc. now owns 2,073 shares of the biopharmaceutical company’s stock valued at $397,000 after acquiring an additional 475 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Alnylam Pharmaceuticals by 110.5% in the fourth quarter. Assenagon Asset Management S.A. now owns 14,166 shares of the biopharmaceutical company’s stock worth $2,712,000 after purchasing an additional 7,436 shares in the last quarter. Raymond James & Associates raised its holdings in Alnylam Pharmaceuticals by 15.1% in the fourth quarter. Raymond James & Associates now owns 14,286 shares of the biopharmaceutical company’s stock worth $2,734,000 after purchasing an additional 1,875 shares in the last quarter. Gateway Investment Advisers LLC raised its holdings in Alnylam Pharmaceuticals by 36.4% in the fourth quarter. Gateway Investment Advisers LLC now owns 19,031 shares of the biopharmaceutical company’s stock worth $3,643,000 after purchasing an additional 5,080 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 51 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Trading Down 3.2 %

NASDAQ:ALNY traded down $4.94 during trading hours on Friday, reaching $149.45. The company had a trading volume of 666,592 shares, compared to its average volume of 702,111. Alnylam Pharmaceuticals, Inc. has a 1-year low of $143.52 and a 1-year high of $218.88. The business’s 50 day moving average price is $160.27 and its 200-day moving average price is $170.47.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. During the same period in the previous year, the firm posted ($1.68) earnings per share. The company’s revenue was up 31.2% compared to the same quarter last year. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -4.61 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $234.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. boosted their target price on shares of Alnylam Pharmaceuticals from $150.00 to $170.00 and gave the stock a “neutral” rating in a report on Thursday, February 1st. Wells Fargo & Company reduced their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a report on Friday, February 16th. StockNews.com upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, March 22nd. Finally, Chardan Capital dropped their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Eight investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $216.12.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.